Galectin Therapeutics Inc.’s GALT share price has dipped by 20.00%, which has investors questioning if this is right time to ...

Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival ("DFS") event-driven interim analysis expected in Q3 2025 Aligned with U.S. Food and Drug Administration ("FDA") on ...

Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer's Disease PRECISE-AD Six Month Interim Results Expected in 1H ...

Adding nivolumab to neoadjuvant chemotherapy significantly improves response rates in high-risk early-stage ER+/HER2− breast ...

The phase 3 trial showed relacorilant with chemotherapy improved progression-free and overall survival in platinum-resistant ...

The fourth cohort of an ongoing phase 1/2 has dosed its first patient with TTX-MC138 in advanced solid tumors.

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension ...

The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...

Patients taking sotatercept had a 76% relative risk reduction in morbidity and mortality events compared with patients taking ...

The equity financing is at a 10% premium to the market share price1 ZÜRICH, SWITZERLAND / ACCESS Newswire / March 31, 2025 ...

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.